The addition of concurrent chemotherapy to cetuximab plus radiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) improves progression-free survival (PFS) compared with cetuximab and radiotherapy alone, according to a recent study.
https://ift.tt/2KjYYz0
Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Παρασκευή 29 Ιουνίου 2018
[News] Concurrent chemotherapy improves outcomes in HNSCC
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου